Half-year report · Q2
4078.TEDINET S100UO2I
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Amended by S100V7D8 (2025-02-07).
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥41.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥82.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥40.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥917m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥885m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥773m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥7.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥121.2bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥125.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥131.6bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥44.1bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥50.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥77.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥75.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥80.7bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥14.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥16.6bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥14.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.2bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥107.71 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-437.65 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-125.53 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥97.23 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 62.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.5% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥910m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥910m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.2bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥38.4bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥37.6bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥798m |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥111m |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥65m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥42.8bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥41.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥910m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥635m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥635m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.1bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥36.8bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥36.3bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥498m |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥136m |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥144m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥41.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥40.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥635m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥2.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 516
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)株式会社日本マスタートラスト信託銀行（信託口） | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区赤坂１丁目８番１号 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（信託口） | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都中央区晴海１丁目８番12号 | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)CGML PB CLIENT ACCOUNT／COLLATERAL（常任代理人 シティバンク、エヌ・エイ東京支店） | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)明治安田生命保険相互会社（常任代理人 株式会社日本カストディ銀行） | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内２丁目１番１号（東京都中央区晴海１丁目８番12号） | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)日本生命保険相互会社（常任代理人 日本マスタートラスト信託銀行株式会社） | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内１丁目６番６号（東京都港区赤坂１丁目８番１号） | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)堺化学取引先持株会 | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)堺市堺区戎島町５丁２番地 | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)RE FUND 107 - CLIENT AC（常任代理人 シティバンク、エヌ・エイ東京支店） | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)モルガン・スタンレーMUFG証券株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)東京都千代田区大手町１丁目９番７号 | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)DFA-INTL-SMALL CAP VALUE PORTFPLIO（常任代理人 シティバンク、エヌ・エイ東京支店） | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)JPモルガン証券株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内２丁目７番３号 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)堺化学工業株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)堺市堺区戎島町５丁２番地 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting policies for preparation of semi annual consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding guarantee obligations (text) | CurrentQuarterInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |